Repaglinide: Difference between revisions
CSV import |
No edit summary |
||
| Line 1: | Line 1: | ||
[[File:Repaglinide.svg|Repaglinide|thumb]] | |||
[[File:Repaglinide ball-and-stick.png|Repaglinide ball-and-stick model|thumb]] | |||
{{intro}} | {{intro}} | ||
Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of [[type 2 diabetes]]. | Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of [[type 2 diabetes]]. | ||
{{livtox}} | {{livtox}} | ||
Repaglinide has been linked to rare instances of clinically apparent acute liver injury. | Repaglinide has been linked to rare instances of clinically apparent acute liver injury. | ||
{{moa}} | {{moa}} | ||
Repaglinide (re pag' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a benzoid acid derivative that, like the sulfonylureas, stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Repaglinide has been shown to reduce the postprandial increase in glucose in patients with [[type 2 diabetes]] and improve glycemic control. Repaglinide | Repaglinide (re pag' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a benzoid acid derivative that, like the sulfonylureas, stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Repaglinide has been shown to reduce the postprandial increase in glucose in patients with [[type 2 diabetes]] and improve glycemic control. Repaglinide | ||
{{fda}} | {{fda}} | ||
{{PAGENAME}} was approved for use in the United States in 1997. The current indications are for management of [[type 2 diabetes]] used in combination with [[diet]] and [[exercise]], with or without other oral [[hypoglycemic agents]]. | {{PAGENAME}} was approved for use in the United States in 1997. The current indications are for management of [[type 2 diabetes]] used in combination with [[diet]] and [[exercise]], with or without other oral [[hypoglycemic agents]]. | ||
{{brand}} | {{brand}} | ||
Repaglinide is available generically and under the brand name [[Prandin]] in tablets of 0.5, 1 and 2 mg. | Repaglinide is available generically and under the brand name [[Prandin]] in tablets of 0.5, 1 and 2 mg. | ||
{{dose}} | {{dose}} | ||
The typical initial dose in adults is 0.5 mg three times daily before meals, with a gradual increase to a maximum of 16 mg daily. | The typical initial dose in adults is 0.5 mg three times daily before meals, with a gradual increase to a maximum of 16 mg daily. | ||
{{se}} | {{se}} | ||
Side effects of repaglinide include [[diarrhea]], [[nausea]], gastrointestinal upset, [[hypoglycemia]], [[headache]], [[dizziness]], arthralgia and [[rash]]. | Side effects of repaglinide include [[diarrhea]], [[nausea]], gastrointestinal upset, [[hypoglycemia]], [[headache]], [[dizziness]], arthralgia and [[rash]]. | ||
{{antidiabetic drugs}} | {{antidiabetic drugs}} | ||
{{coststubd}} | {{coststubd}} | ||
{{Oral hypoglycemics}} | |||
{{Ion channel modulators}} | |||
{{Portal bar | Medicine}} | |||
[[Category:Potassium channel blockers]] | |||
[[Category:Meglitinides]] | |||
[[Category:1-Piperidinyl compounds]] | |||
[[Category:Phenol ethers]] | |||
[[Category:Acetamides]] | |||
[[Category:Benzoic acids]] | |||
[[Category:Ethoxy compounds]] | |||
[[Category:Drugs developed by Novo Nordisk]] | |||
[[Category:Isobutyl compounds]] | |||
Latest revision as of 03:47, 22 March 2025
Information about Repaglinide[edit]
Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes.
Liver safety of Repaglinide[edit]
Repaglinide has been linked to rare instances of clinically apparent acute liver injury.
Mechanism of action of Repaglinide[edit]
Repaglinide (re pag' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a benzoid acid derivative that, like the sulfonylureas, stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Repaglinide has been shown to reduce the postprandial increase in glucose in patients with type 2 diabetes and improve glycemic control. Repaglinide
FDA approval information for Repaglinide[edit]
Repaglinide was approved for use in the United States in 1997. The current indications are for management of type 2 diabetes used in combination with diet and exercise, with or without other oral hypoglycemic agents.
Brand name for Repaglinide[edit]
Repaglinide is available generically and under the brand name Prandin in tablets of 0.5, 1 and 2 mg.
Dosage and administration for Repaglinide[edit]
The typical initial dose in adults is 0.5 mg three times daily before meals, with a gradual increase to a maximum of 16 mg daily.
Side effects of Repaglinide[edit]
Side effects of repaglinide include diarrhea, nausea, gastrointestinal upset, hypoglycemia, headache, dizziness, arthralgia and rash. Antidiabetics
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Insulin
- Metformin
- Metiglinide Analogues
- Pramlintide
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors
- Sulfonylureas
- First Generation Sulfonylureas
- Acetohexamide
- Chlorpropamide
- Tolazamide
- Tolbutamide
- Second Generation Sulfonylureas
- Gliclazide
- Glimepiride
- Glipizide
- Glyburide (Glibenclamide)
- First Generation Sulfonylureas
- Thiazolidinediones
